Roivant Sciences (ROIV) Net Cash Flow (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Net Cash Flow came in at -$1.2 billion in Q4 2025, up 72.76% YoY from -$717.4 million in Q4 2024, and down 46579.55% on a QoQ basis from -$2.7 million in Q3 2025.
Roivant Sciences (ROIV) Net Cash Flow (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Net Cash Flow data on file, last reported at -$1.2 billion in Q4 2025.
- Quarterly Net Cash Flow rose 72.76% year-over-year to -$1.2 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$2.7 billion (up 70.03% YoY) and the FY2026 annual result came in at -$1.3 billion, up 66.06% from the prior year.
- Net Cash Flow fell to -$1.2 billion in Q4 2025, from -$2.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $5.0 billion in Q4 2023 to a low of -$4.6 billion in Q4 2024.
- A 5-year average of -$507.4 million and a median of -$242.4 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 1036.57% — and 2024, when it plunged 14574.37%.
- Tracing ROIV's Net Cash Flow over 5 years: stood at $84.5 million in 2021, then tumbled by 731.07% to -$533.0 million in 2022, then soared by 1036.57% to $5.0 billion in 2023, then slumped by 191.15% to -$4.6 billion in 2024, then soared by 72.76% to -$1.2 billion in 2025.
- The last three Net Cash Flow figures came in at -$1.2 billion (Q4 2025), -$2.7 million (Q3 2025), and -$1.5 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -170.75 Mn |
| Jun 30, 2026 | -170.75 Mn |
| Dec 31, 2025 | -1.24 Bn |
| Dec 31, 2025 | -1.24 Bn |
| Sep 30, 2025 | -2.66 Mn |
| Sep 30, 2025 | -2.66 Mn |
| Jun 30, 2025 | -1.48 Bn |
| Jun 30, 2025 | -1.48 Bn |
| Dec 31, 2024 | -4.55 Bn |
| Dec 31, 2024 | -4.55 Bn |
| Sep 30, 2024 | -3.67 Bn |
| Sep 30, 2024 | -3.67 Bn |
| Jun 30, 2024 | -854.41 Mn |
| Jun 30, 2024 | -854.41 Mn |
| Dec 31, 2023 | 4.99 Bn |
| Dec 31, 2023 | 4.99 Bn |
| Sep 30, 2023 | -25.01 Mn |
| Sep 30, 2023 | -25.01 Mn |
| Jun 30, 2023 | -242.35 Mn |
| Jun 30, 2023 | -242.35 Mn |